What is Synthego's biggest risk?

The biggest risk is being outcompeted on price and scale by giant life-science suppliers. Thermo Fisher Scientific, Danaher's Integrated DNA Technologies, Merck KGaA/MilliporeSigma, Agilent, and GenScript all sell guide RNA and GMP reagents at much larger volumes. GenScript Biotech alone posted $594.5 million in 2024 revenue, dwarfing Synthego, which has raised $450-472 million in total venture equity since 2012 (as of June 2025) and employed just 172 people as of June 2026. Our July 2026 assessment found little structurally protecting Synthego from these larger rivals taking share.

Is Synthego in financial trouble?

It went through real financial trouble, filing Chapter 11 bankruptcy on May 5, 2025, and getting acquired via credit bid for roughly $85 million by Perceptive Advisors, closing July 18, 2025. As of July 2026 it is operating under new ownership with a much smaller headcount than before, so the current status is better described as recovering rather than in trouble, though the rebuild is unproven.

Who are Synthego's biggest competitors?

Its main competitors are much larger life-science companies: Thermo Fisher Scientific, Danaher's Integrated DNA Technologies, Merck KGaA/MilliporeSigma, Agilent, and GenScript. For scale comparison, peer GenScript Biotech alone posted $594.5 million in 2024 revenue, dwarfing Synthego's size, which raised $450-472 million in total venture equity since 2012 as of June 2025.

Is Synthego at risk from AI?

AI does not appear to be a direct threat to Synthego. AI-driven protein and CRISPR design tools are more likely to increase demand for synthesized guide RNA than replace the need for it, so the AI threat status is listed as not applicable rather than a risk to watch.

Does Synthego have any competitive advantages?

Yes, it has a working cGMP manufacturing facility, live pharma partnerships with AstraZeneca and Base Therapeutics, and a notable patent litigation win over Agilent in April 2026 that invalidated two of Agilent's guide RNA chemistry patents. Even so, our July 2026 assessment found that pressure from larger rivals like Thermo Fisher Scientific and Danaher's Integrated DNA Technologies remains significant, since they operate guide RNA and GMP oligo manufacturing at far larger scale with no clear structural barrier stopping them from taking share.

What should I watch to see if Synthego is turning around?

Two dated checkpoints matter: whether Synthego posts two consecutive years of headcount growth under Perceptive Advisors ownership by July 2027, and whether it signs a multi-year GMP supply contract tied to a Phase 3 CRISPR therapeutic program by December 2026. These would be concrete signs the post-bankruptcy rebuild is gaining traction rather than just stabilizing at its current 172-employee size as of June 2026.

Biotech tools companies · subsidiary of Perceptive Advisors (via affiliate ownership post-bankruptcy asset purchase, July 18, 2025) · United States

Synthego Corporation

synthego.com ↗

Makes synthetic guide RNA and CRISPR editing kits for labs and biopharma.

Little protection left

Assessed 30 July 2026 · Evidence as of 30 July 2026

Not much stands between this business and its pressures.

On the recordSince 30 July 2026 · Checkable from August 31, 2026 · Every call on the record Checkpoint: Bankruptcy estate claims-objection deadline

The call

Synthego survived Chapter 11 as a smaller, Perceptive-owned company still selling guide RNA into a market that giants like Danaher and Thermo Fisher already dominate.

Synthego designed lab equipment and software to help scientists edit genes more easily. The company burned through $450 million in investor money but could not make enough profit to survive, especially when it competed against much larger companies like Thermo Fisher and Danaher that already owned the same market space and had more customers and resources. The company filed for bankruptcy in May 2025, and a private equity firm called Perceptive Advisors took control with an $85 million bid; old shareholders lost almost everything. The one thing that could change this is if a big buyer like Thermo Fisher or Danaher decides to buy Synthego's pieces, or if the new owners find major customers willing to sign long term deals, though neither seems likely given the company shrank from 300 employees to around 150 to 190.

Why

AI pressure: Open-source ML guide-RNA design tools and foundation models. Free or cheap AI design tools chip at the machine-learning pricing premium Synthego once charged for guide RNA. Could AI do the core job? Only partly.

Bigger players: Danaher (IDT), Thermo Fisher Scientific, Merck KGaA, Agilent, Revvity. These labs-supply giants already sell competing guide RNA and CRISPR reagents with far more cash and reach. Could a giant copy it? Yes, easily.

What protects it. GMP-grade guide RNA manufacturing and existing biopharma relationships, though unit economics remain unproven.

What would change this call

Perceptive Advisors announces a sale of Synthego to Danaher, Thermo Fisher, or Revvity within 12 months. Would show the asset was restructured for exit, not independent growth.
Synthego headcount continues falling below 174 or open roles stay near zero through 2026. Would confirm continued cost-cutting rather than reinvestment.
Bankruptcy estate claims-objection process closes August 31, 2026 with recovery still near 4.4%. Would confirm creditors saw the pre-bankruptcy business as largely unviable.

Key numbers

Perceptive bought Synthego via $85M credit bid (2025-07-18)
Old creditors recovered about 4.4% of claims (2026-07-20)
Headcount fell to 174, from about 300 in 2021 (2026-07-23)

Named risks

Legacy debtor Shapauste Inc. remains in liquidation with claims-objection deadline August 31, 2026. Severity: high
PE-controlled restructuring under Perceptive Advisors caps upside and raises exit-sale risk. Severity: medium
Headcount contracted from ~300 (2021) to 174 (2026) with unproven post-bankruptcy unit economics. Severity: high
ML guide-RNA design differentiation eroding as commodity AI/bio-AI tools proliferate. Severity: medium
Potential renewed Agilent litigation via related continuation patents. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Danaher (IDT)	losing to	Synthego filed Chapter 11 May 5, 2025 while IDT continued selling competing synthetic guide RNAs at scale
Agilent Technologies	contesting	Federal Circuit affirmed invalidation of two Agilent CRISPR guide-RNA patents in Synthego's favor, June 11, 2025
Thermo Fisher Scientific	losing to	Larger reagent incumbent operating unaffected while Synthego shrank to 174 employees by July 2026
Revvity (Horizon Discovery)	losing to	Horizon Discovery gained scale via Perkin-Elmer's $383M acquisition in Nov 2020, ahead of Synthego's 2025 bankruptcy
Merck KGaA	losing to	Established reagent conglomerate competing in same CRISPR tools category as bankrupt Synthego, 2025

Questions people ask

What is Synthego's biggest risk?: The biggest risk is being outcompeted on price and scale by giant life-science suppliers. Thermo Fisher Scientific, Danaher's Integrated DNA Technologies, Merck KGaA/MilliporeSigma, Agilent, and GenScript all sell guide RNA and GMP reagents at much larger volumes. GenScript Biotech alone posted $594.5 million in 2024 revenue, dwarfing Synthego, which has raised $450-472 million in total venture equity since 2012 (as of June 2025) and employed just 172 people as of June 2026. Our July 2026 assessment found little structurally protecting Synthego from these larger rivals taking share.
Is Synthego in financial trouble?: It went through real financial trouble, filing Chapter 11 bankruptcy on May 5, 2025, and getting acquired via credit bid for roughly $85 million by Perceptive Advisors, closing July 18, 2025. As of July 2026 it is operating under new ownership with a much smaller headcount than before, so the current status is better described as recovering rather than in trouble, though the rebuild is unproven.
Who are Synthego's biggest competitors?: Its main competitors are much larger life-science companies: Thermo Fisher Scientific, Danaher's Integrated DNA Technologies, Merck KGaA/MilliporeSigma, Agilent, and GenScript. For scale comparison, peer GenScript Biotech alone posted $594.5 million in 2024 revenue, dwarfing Synthego's size, which raised $450-472 million in total venture equity since 2012 as of June 2025.
Is Synthego at risk from AI?: AI does not appear to be a direct threat to Synthego. AI-driven protein and CRISPR design tools are more likely to increase demand for synthesized guide RNA than replace the need for it, so the AI threat status is listed as not applicable rather than a risk to watch.
Does Synthego have any competitive advantages?: Yes, it has a working cGMP manufacturing facility, live pharma partnerships with AstraZeneca and Base Therapeutics, and a notable patent litigation win over Agilent in April 2026 that invalidated two of Agilent's guide RNA chemistry patents. Even so, our July 2026 assessment found that pressure from larger rivals like Thermo Fisher Scientific and Danaher's Integrated DNA Technologies remains significant, since they operate guide RNA and GMP oligo manufacturing at far larger scale with no clear structural barrier stopping them from taking share.
What should I watch to see if Synthego is turning around?: Two dated checkpoints matter: whether Synthego posts two consecutive years of headcount growth under Perceptive Advisors ownership by July 2027, and whether it signs a multi-year GMP supply contract tied to a Phase 3 CRISPR therapeutic program by December 2026. These would be concrete signs the post-bankruptcy rebuild is gaining traction rather than just stabilizing at its current 172-employee size as of June 2026.

Timeline

2026-01-13Entered molecular biology and clinical diagnostic reagents market via biotechrabbit GmbH collaboration
2025-07-18Sale of Synthego to Perceptive Advilots via ~$85M credit bid closed
2025-06-11Federal Circuit affirmed invalidation of two Agilent CRISPR guide-RNA patents in Synthego's favor
2025-05-05Synthego filed Chapter 11 bankruptcy in Delaware
2024-03Divested Engineered Cells business to Telegraph Hill Partners, forming EditCo Bio; Craig Christianson named CEO
2022-11Cut about 20% of workforce (~105 employees) amid biotech downturn
2022-02Closed $200M Series E led by Perceptive Advisors, SoftBank Vision Fund 2, Wellington
2020-08Closed $100M Series D led by Wellington Management
2018-10Closed $110M Series C led by Founders Fund
2017-01Closed $41M Series B led by 8VC

Head to head

GenScript Biotech vs Synthego Corporation

Revision history

30 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Singular Genomics Standard BioTools T2 Biosystems, Inc.